BlackRock
ZBIO

BlackRock’s Zenas BioPharma ZBIO Stock Holding History

BlackRock’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.8M Buy
2,037,548
+270,030
+15% +$6.06M ﹤0.01% 2660
2025
Q4 		$64.2M Buy
1,767,518
+538,877
+44% +$17.7M ﹤0.01% 2364
2025
Q3 		$27.3M Buy
1,228,641
+133,032
+12% +$2.17M ﹤0.01% 2897
2025
Q2 		$10.6M Buy
1,095,609
+81,499
+8% +$794K ﹤0.01% 3388
2025
Q1 		$8.01M Buy
1,014,110
+7,552
+0.8% +$59.1K ﹤0.01% 3430
2024
Q4 		$8.24M Buy
+1,006,558
New +$15.7M ﹤0.01% 3525

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock's ZBIO Position: Q1 2026 in Review

BlackRock increased its Zenas BioPharma (ZBIO) stake by 15% in Q1 2026, buying an estimated $6.06M and bringing the position to 2,037,548 shares worth $39.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2660.

BlackRock first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $64.2M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • BlackRock held 2,037,548 shares of Zenas BioPharma worth $39.8M as of Q1 2026.
  • BlackRock bought 270,030 Zenas BioPharma shares in Q1 2026, an estimated $6.06M.
  • Zenas BioPharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2660 holding.
  • BlackRock first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • BlackRock's Zenas BioPharma position peaked at $64.2M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.